Compare Becton Dickinson and Co (BDX) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Gitlab Inc — how do they compare? Becton Dickinson and Co trades at $179.27 (market cap $49.41B), while Gitlab Inc trades at $41.24 (market cap $7.11B). The key difference: Becton Dickinson and Co is far larger — about 6.9× Gitlab Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| BDX | GTLB | |
|---|---|---|
Market Cap | $49.41B | $7.11B |
Sector | Health | Technology |
52-Week High | $185.39 | $51.04 |
52-Week Low | $138.62 | $19.42 |
Enterprise Value | $65.51B | $5.85B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
GitLab (GTLB) trades at $40.73, up 4.52% today, with a bullish technical signal from moving averages and a consensus analyst price target of $32.92. Recent earnings beats in Q3 2025 to Q1 2026 highlight strong execution, while revenue grew to $759.25 million in 2025. The stock's high P/E of 521.22 reflects growth expectations, but negative net income and cash flow pose challenges.
Outlook: Growth in DevSecOps and AI-driven software demand supports upside, but profitability risks and high valuation require caution. Key catalysts include continued revenue expansion and path to positive cash flow, while competition and execution missteps are primary risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
